<DOC>
	<DOCNO>NCT01209195</DOCNO>
	<brief_summary>This study Phase 1 pharmacologic open-labeled dose-escalation trial MM-121 combination paclitaxel use `` 3+3 '' design .</brief_summary>
	<brief_title>A Study MM-121 Combination With Paclitaxel Patients With Advanced Gynecologic Breast Cancers</brief_title>
	<detailed_description>Successive cohort three patient treat escalate dos maximum tolerate dose/recommended phase 1 dose identify . Once maximum tolerate dose identify , Expansion Cohort enrol dose characterize safety explore pharmacodynamic endpoint .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Cytological histological confirmation locally advanced/metastatic recurrent epithelial ovarian cancer , fallopian tube cancer , primary peritoneal cancer endometrial cancer ; OR , cytological histological confirmation locally advance /metastatic Her2 nonoverexpressing breast cancer Eighteen year age Candidates chemotherapy Able understand sign inform consent ( legal representative able ) Measurable disease accord RECIST v1.1 ECOG Performance Score ( PS ) ≤ 2 Willing abstain sexual intercourse use effective form contraception study 90 day follow last dose MM121 Prior radiation therapy &gt; 25 % bone marrowbearing area Evidence active malignancy Active infection fever &gt; 38.5°C screen visit first schedule day dose Symptomatic CNS disease Known hypersensitivity component MM121 hypersensitivity reaction fully human monoclonal antibody Received treatment , within 30 day prior first schedule day dose , investigational agent receive regulatory approval indication disease state Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>HER-2 negative breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Fallopian tube cancer</keyword>
</DOC>